Natalie A. Diepenhorst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Natalie A. Diepenhorst has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Paul R. Gooley
Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Australia
2 shared publications Amy Wang
The National Center for Advancing Translational Sciences, Division of Preclinical Innovation, National Institutes of Health, Rockville, Maryland 20850
1 shared publication- Brad Astbury
Department of Health Systems, Policy and Economics, Melbourne School of Public Health, University of Melbourne, Victoria, Australia
1 shared publication Catherine Z. Chen
The National Center for Advancing Translational Sciences, Division of Preclinical Innovation, National Institutes of Health, Rockville, Maryland 20850
1 shared publication- Claire Nightingale
Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
1 shared publication Emma J. Petrie
The Department of Biochemistry and Molecular Biology, and
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Health Expectations
- Vol. 29 (5) , e70859
Embedding Consumer‐Led Research in a Comprehensive Cancer Centre Alliance: A Mixed‐Methods Evaluation
Introduction: As consumer involvement becomes increasingly recognised as an important part of health and medical research, new ways to involve consumers are actively being explored. This evaluation aimed to investigate the experience of consumers and other stakeholders involved in two pilot consumer‐led research projects within a comprehensive cancer alliance. Methods: The evaluation consisted of program document review, an online survey and individual interviews to explore the experience of a range of stakeholders. Analysis was via a convergent mixed methods approach. Results: Overall, 12 consumer participants and 11 other non‐consumer stakeholder participants took part in the evaluation. An in‐depth narrative of participants’ experiences was developed, from which five key components of effective consumer‐led research were identified: (1) Organisational commitment to consumer involvement at all levels, (2) appropriate time and resources, (3) training and education, (4) clearly defined roles and responsibilities, and (5) an ecosystem that values individuals and creates a cohesive group dynamic. While the two pilot projects shared similarities, their iterative and sequential nature enabled learnings from the first to be applied in real time to the second. Overall, the experience of the programs was positive, with both consumers and other stakeholders rating the pilots as successful and stating they were highly likely to recommend the program to others. Conclusion: This evaluation illustrated that the implementation of a framework for consumer‐led research pilot projects was perceived positively and enhanced consumer leadership in the research process. Additionally, it identified areas where power and decision‐making could be more evenly shared, thereby enhancing consumer leadership in the research process. Patient or Public Contribution: People with lived experience of cancer (including service users and caregivers) were involved in this evaluation in two ways. First, two consumers were part of the Victorian Comprehensive Cancer Centre Alliance evaluation team (L.L. and N.D.) and helped design the evaluation plan and data collection tools and reviewed findings and draft reports. N.D. contributed to the manuscript write‐up. Second, consumers who were part of the two pilot projects and had roles in consumer‐led research projects ( n = 17) were invited to participate in the evaluation activities (online survey and/or interview) to share their experience. These consumers were also invited to an online feedback session with the evaluation team to sense‐check and confirm the evaluation findings prior to finalisation.
- 8 September 2026
- Published by Wiley in Health Expectations
- Vol. 29 (5) , e70859
Open AccessEmbedding Consumer‐Led Research in a Comprehensive Cancer Centre Alliance: A Mixed‐Methods Evaluation
Introduction: As consumer involvement becomes increasingly recognised as an important part of health and medical research, new ways to involve consumers are actively being explored. This evaluation aimed to investigate the experience of consumers and other stakeholders involved in two pilot consumer‐led research projects within a comprehensive cancer alliance. Methods: The evaluation consisted of program document review, an online survey and individual interviews to explore the experience of a range of stakeholders. Analysis was via a convergent mixed methods approach. Results: Overall, 12 consumer participants and 11 other non‐consumer stakeholder participants took part in the evaluation. An in‐depth narrative of participants’ experiences was developed, from which five key components of effective consumer‐led research were identified: (1) Organisational commitment to consumer involvement at all levels, (2) appropriate time and resources, (3) training and education, (4) clearly defined roles and responsibilities, and (5) an ecosystem that values individuals and creates a cohesive group dynamic. While the two pilot projects shared similarities, their iterative and sequential nature enabled learnings from the first to be applied in real time to the second. Overall, the experience of the programs was positive, with both consumers and other stakeholders rating the pilots as successful and stating they were highly likely to recommend the program to others. Conclusion: This evaluation illustrated that the implementation of a framework for consumer‐led research pilot projects was perceived positively and enhanced consumer leadership in the research process. Additionally, it identified areas where power and decision‐making could be more evenly shared, thereby enhancing consumer leadership in the research process. Patient or Public Contribution: People with lived experience of cancer (including service users and caregivers) were involved in this evaluation in two ways. First, two consumers were part of the Victorian Comprehensive Cancer Centre Alliance evaluation team (L.L. and N.D.) and helped design the evaluation plan and data collection tools and reviewed findings and draft reports. N.D. contributed to the manuscript write‐up. Second, consumers who were part of the two pilot projects and had roles in consumer‐led research projects ( n = 17) were invited to participate in the evaluation activities (online survey and/or interview) to share their experience. These consumers were also invited to an online feedback session with the evaluation team to sense‐check and confirm the evaluation findings prior to finalisation.
- Open Access
- 1 December 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (50) , 34938-34952
Investigation of Interactions at the Extracellular Loops of the Relaxin Family Peptide Receptor 1 (RXFP1)
- 1 December 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (50) , 34938-34952
Open AccessInvestigation of Interactions at the Extracellular Loops of the Relaxin Family Peptide Receptor 1 (RXFP1)
- Open Access
- 11 January 2014
- Published by Firenze University Press in Italian Journal of Anatomy and Embryology
- Vol. 118, 1-3
Development of a scaffold displaying exoloops of RXFP1
Relaxin family peptide receptor 1 (RXFP1), the cognate receptor for relaxin, is a G-protein coupled receptor (GPCR) possessing a unique extracellular region consisting of a domain of 10 leucine rich repeats (LRRs) linked to an N-terminal low density lipoprotein Class A module. Relaxin binds to its receptor primarily by a high affinity interaction with the LRRs. An additional low-affinity interaction has been proposed to occur between relaxin and the the exoloops (ELs) of the transmembrane domain, however the molecular detail of this interaction remains undefined. While site directed mutagenesis and subsequent functional characterisation of these mutants traditionally allows identification of residues contributing to receptor function, in this case results are complicated by the presence of the high affinity binding site in the LRRs. To create a tool to investigate the low-affinity interaction, a protein scaffold system displaying exoloops 1 and 2 from RXFP1 was designed. This was achieved by inserting RXFP1 exoloops 1 and 2 into the native loops of a thermostabilised 6 kDa GB1 protein creating EL1/EL2-GB1. This protein has been expressed and purified in milligram quantities and used in conjunction with biophysical techniques such as NMR to explore relaxin binding to the exoloops of RXFP1.
- 11 January 2014
- Published by Firenze University Press in Italian Journal of Anatomy and Embryology
- Vol. 118, 1-3
Open AccessDevelopment of a scaffold displaying exoloops of RXFP1
Relaxin family peptide receptor 1 (RXFP1), the cognate receptor for relaxin, is a G-protein coupled receptor (GPCR) possessing a unique extracellular region consisting of a domain of 10 leucine rich repeats (LRRs) linked to an N-terminal low density lipoprotein Class A module. Relaxin binds to its receptor primarily by a high affinity interaction with the LRRs. An additional low-affinity interaction has been proposed to occur between relaxin and the the exoloops (ELs) of the transmembrane domain, however the molecular detail of this interaction remains undefined. While site directed mutagenesis and subsequent functional characterisation of these mutants traditionally allows identification of residues contributing to receptor function, in this case results are complicated by the presence of the high affinity binding site in the LRRs. To create a tool to investigate the low-affinity interaction, a protein scaffold system displaying exoloops 1 and 2 from RXFP1 was designed. This was achieved by inserting RXFP1 exoloops 1 and 2 into the native loops of a thermostabilised 6 kDa GB1 protein creating EL1/EL2-GB1. This protein has been expressed and purified in milligram quantities and used in conjunction with biophysical techniques such as NMR to explore relaxin binding to the exoloops of RXFP1.